UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Annals of internal medicine, ISSN 0003-4819, 06/2016, Volume 164, Issue 11, pp. 705 - 714
Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptides - adverse effects | Humans | Middle Aged | Risk Factors | Male | Hospitalization | Sulfonylurea Compounds - adverse effects | Thiazolidinediones - adverse effects | Female | Retrospective Studies | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Heart Failure - chemically induced | Adamantane - adverse effects | Adamantane - analogs & derivatives | Sitagliptin Phosphate - adverse effects | Heart failure | Complications and side effects | Hospital care | Sitagliptin | Forecasts and trends | Risk factors | Saxagliptin | Prescription drugs | Cardiology | Risk assessment | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 376 - 383
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Benzhydryl Compounds - administration & dosage | Humans | Middle Aged | Male | Metformin - adverse effects | Benzhydryl Compounds - adverse effects | Urinary Tract Infections - chemically induced | Adult | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Drug Therapy, Combination | Hypoglycemia - chemically induced | Glucosides - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Double-Blind Method | Dipeptides - adverse effects | Treatment Outcome | Blood Glucose - drug effects | Dipeptides - administration & dosage | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Care and treatment | Usage | Analysis | Clinical trials | Dosage and administration | Glycemic index | Metformin | Saxagliptin | Drug therapy | Diabetes | Index Medicus
Journal Article
Diabetes care, ISSN 0149-5992, 11/2015, Volume 38, Issue 11, pp. 2009 - 2017
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypoglycemia - epidemiology | Metformin - therapeutic use | Benzhydryl Compounds - administration & dosage | Humans | Middle Aged | Male | Metformin - adverse effects | Diabetes Mellitus, Type 2 - epidemiology | Benzhydryl Compounds - adverse effects | Hypoglycemic Agents - administration & dosage | Urinary Tract Infections - chemically induced | Adamantane - therapeutic use | Adult | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Hypoglycemia - chemically induced | Glucosides - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Dipeptides - therapeutic use | Double-Blind Method | Dipeptides - adverse effects | Treatment Outcome | Blood Glucose - drug effects | Dipeptides - administration & dosage | Urinary Tract Infections - epidemiology | Drug Therapy, Combination - methods | Glucosides - administration & dosage | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Treatment outcome | Usage | Safety and security measures | Dapagliflozin | Analysis | Clinical trials | Dosage and administration | Metformin | Saxagliptin | Prescription drugs | Diabetes | Comparative analysis | Index Medicus
Journal Article
Diabetes care, ISSN 0149-5992, 02/2017, Volume 40, Issue 2, pp. 284 - 286
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Sitagliptin Phosphate - administration & dosage | Acute Disease | Piperidines - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Pancreatitis - epidemiology | Dipeptides - adverse effects | Humans | Pancreatitis - chemically induced | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Incidence | Randomized Controlled Trials as Topic | Dipeptides - administration & dosage | Uracil - administration & dosage | Uracil - adverse effects | Piperidines - adverse effects | Adamantane - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Adamantane - adverse effects | Adamantane - analogs & derivatives | Sitagliptin Phosphate - adverse effects | Uracil - analogs & derivatives | Type 2 diabetes | Diabetics | Treatment outcome | Care and treatment | Analysis | Pancreatitis | Health aspects | Risk factors | Cardiovascular system | Clinical trials | Medical treatment | Risk assessment | Index Medicus
Journal Article
Expert opinion on drug safety, ISSN 1474-0338, 07/2012, Volume 11, Issue 4, pp. 597 - 614
Type 2 diabetes | thiazolidinedione | sulphonylurea | hypoglycaemia | DPP-4 inhibitor | GLP-1 agonist | metformin | Hypoglycaemia | Sulphonylurea | Metformin | Thiazolidinedione | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Pharmacogenetics | Venoms - adverse effects | Dipeptides - adverse effects | Humans | Sulfonylurea Compounds - adverse effects | Thiazolidinediones - adverse effects | Metformin - adverse effects | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemia - chemically induced | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Index Medicus | Drugs | Enzymes | Side effects | Reviews | Antibiotics | Diabetes mellitus | Psychology | Risk factors | Stress
Journal Article
Clinical therapeutics, ISSN 0149-2918, 2014, Volume 36, Issue 12, pp. 2072 - 2079
Internal Medicine | Medical Education | DPP-IV inhibition | cardiovascular disease | heart failure | type 2 diabetes | Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) | Vildagliptin in Ventricular Dysfunction Diabetes Trial (VIVIDD) | Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial | Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Cardiology. Vascular system | Heart | Diabetes. Impaired glucose tolerance | Pharmacology. Drug treatments | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Heart failure, cardiogenic pulmonary edema, cardiac enlargement | Coronary heart disease | Endocrine pancreas. Apud cells (diseases) | Dipeptides - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptides - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Pyrrolidines - adverse effects | Uracil - therapeutic use | Hospitalization | Pyrrolidines - therapeutic use | Uracil - adverse effects | Piperidines - therapeutic use | Piperidines - adverse effects | Adamantane - therapeutic use | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Heart Failure - chemically induced | Adamantane - adverse effects | Adamantane - analogs & derivatives | Nitriles - therapeutic use | Sitagliptin Phosphate - adverse effects | Uracil - analogs & derivatives | Heart failure | Regulatory agencies | Heart attacks | Peptides | Mortality | Cardiovascular disease | FDA approval | Patients | Studies | Databases | Diabetes | Drug therapy | Acute coronary syndromes | Index Medicus
Journal Article
Contemporary clinical trials, ISSN 1551-7144, 2011, Volume 32, Issue 3, pp. 324 - 332
Hematology, Oncology and Palliative Medicine | Cardiovascular | Saxagliptin and liraglutide | Sitagliptin | Alogliptin | Vildagliptin | Insulin inhalation powder | Exenatide | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Diabetes. Impaired glucose tolerance | General and cellular metabolism. Vitamins | Pharmacology. Drug treatments | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Triazoles - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | United States | Humans | Pyrrolidines - adverse effects | Allylamine - adverse effects | Randomized Controlled Trials as Topic - standards | Time Factors | Investigational New Drug Application - legislation & jurisprudence | Sitagliptin Phosphate | Incretins - chemistry | Colesevelam Hydrochloride | Incretins - physiology | United States Food and Drug Administration | Adamantane - adverse effects | Adamantane - analogs & derivatives | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Dipeptides - adverse effects | Allylamine - analogs & derivatives | Uracil - adverse effects | Piperidines - adverse effects | Pyrazines - adverse effects | Cardiovascular Diseases - chemically induced | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Nitriles - adverse effects | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Liraglutide | Peptides - adverse effects | Practice Guidelines as Topic | Uracil - analogs & derivatives | Type 2 diabetes | Hypoglycemic agents | Drug therapy | Cardiovascular diseases | Drug approval | Risk factors | Diabetes therapy | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1317 - 1326
no | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | General aspects | Diabetes. Impaired glucose tolerance | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Adamantane - therapeutic use | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Hypoglycemia - chemically induced | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Dipeptides - therapeutic use | Double-Blind Method | Pancreatitis - epidemiology | Dipeptides - adverse effects | Kaplan-Meier Estimate | Pancreatitis - chemically induced | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Patient outcomes | Dosage and administration | Drug therapy | Heart diseases | Risk factors | Saxagliptin | Myocardial infarction | Cerebral infarction | Heart attacks | Peptidase | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Angina | Patients | Heart rate | Ischemia | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article
Endocrine practice, ISSN 1530-891X, 11/2013, Volume 19, Issue 6, pp. 1025 - 1034
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Triazoles - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Pyrrolidines - adverse effects | Pyrazines - metabolism | Pyrazines - therapeutic use | Renal Insufficiency, Chronic - complications | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Pyrrolidines - therapeutic use | Renal Insufficiency, Chronic - drug therapy | Renal Insufficiency, Chronic - metabolism | Quinazolines - metabolism | Pyrrolidines - metabolism | Adamantane - therapeutic use | Linagliptin | Purines - adverse effects | Purines - therapeutic use | Dipeptides - metabolism | Sitagliptin Phosphate | Diabetes Mellitus, Type 2 - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Nitriles - metabolism | Dipeptides - therapeutic use | Piperidines - metabolism | Purines - metabolism | Adamantane - metabolism | Dipeptides - adverse effects | Uracil - therapeutic use | Triazoles - metabolism | Uracil - adverse effects | Piperidines - therapeutic use | Quinazolines - therapeutic use | Piperidines - adverse effects | Pyrazines - adverse effects | Quinazolines - adverse effects | Uracil - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Nitriles - therapeutic use | Uracil - analogs & derivatives
Journal Article
Diabetes care, ISSN 0149-5992, 11/2015, Volume 38, Issue 11, pp. 2018 - 2024
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypoglycemia - epidemiology | Benzhydryl Compounds - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Metformin - adverse effects | Diabetes Mellitus, Type 2 - epidemiology | Benzhydryl Compounds - adverse effects | Hypoglycemic Agents - administration & dosage | Adult | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Hypoglycemia - chemically induced | Glucosides - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Double-Blind Method | Dipeptides - adverse effects | Treatment Outcome | Blood Glucose - drug effects | Dipeptides - administration & dosage | Drug Therapy, Combination - methods | Glucosides - administration & dosage | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Treatment outcome | Usage | Dapagliflozin | Analysis | Clinical trials | Dosage and administration | Metformin | Drug therapy | Saxagliptin | Hemoglobin | Prescription drugs | Diabetes | Safety | Index Medicus
Journal Article